An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases

ISSN： 0043-5341

Source： Wiener Medizinische Wochenschrift, Vol.160, Iss.17-18, 2010-09, pp. : 458-463

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Osteoporosis in inflammatory joint diseases

By Roux C.

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 421-433

Springer Publishing Company

Access to resources Recommend Favorite

Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases

Reviews on Recent Clinical Trials, Vol. 1, Iss. 3, 2006-09 ,pp. : 193-200

Bentham Science Publishers

Access to resources Recommend Favorite

Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases

By Alten Rieke Maleitzke Tazio

Annals of Medicine, Vol. 45, Iss. 4, 2013-06 ,pp. : 357-363

Informa Healthcare

Access to resources Recommend Favorite

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 1, 2015-07 ,pp. : 40-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

New strategies for the treatment of inflammatory bowel diseases

By Roblin Xavier Dronne William Paul Stéphane Tedesco Emilie Del

Clinical Investigation, Vol. 3, Iss. 5, 2013-05 ,pp. : 479-492

Future Science

Access to resources Recommend Favorite